Publications & Posters
Scholarly publications
Spinal Muscular Atrophy
Apitegromab
July 2021
International Journal of Toxicology
Preclinical Safety Assessment and Toxicokinetics of Apitegromab, an Antibody Targeting Proforms of Myostatin for the Treatment of Muscle-Atrophying Disease
Spinal Muscular Atrophy
Apitegromab
June 2021
Virtual 2021 7th Congress of the European Academy of Neurology (EAN)
Apitegromab, an Investigational Anti-proMyostatin Monoclonal Antibody for Spinal Muscular Atrophy: Phase 2 Results (Presentation)
Immuno-Oncology
SRK-181
June 2021
2021 American Society of Clinical Oncology (ASCO) Annual Meeting
First-in-Human Phase 1 Trial (DRAGON) of SRK-181: A Potential First-in-Class Selective Latent TGFβ1 Inhibitor, Alone or in Combination with Anti-PD-(L)1 Treatment in Patients with Advanced Solid Tumors
Spinal Muscular Atrophy
Apitegromab
May 2021
16th International Congress on Neuromuscular Diseases (ICNMD 2021)
TOPAZ: Phase 2 Study Evaluating Efficacy and Safety of Apitegromab in Later-Onset Spinal Muscular Atrophy; An Interim Analysis
Spinal Muscular Atrophy
Apitegromab
May 2021
Advances in Therapy
A Randomized Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of the Novel Myostatin Inhibitor Apitegromab (SRK-015): A Potential Treatment for Spinal Muscular Atrophy
Spinal Muscular Atrophy
Apitegromab
April 2021
2021 Virtual American Academy of Neurology (AAN) Annual Meeting
